Decision-Making for Preventive Interventions in Asymptomatic Patients.


Journal

Stroke
ISSN: 1524-4628
Titre abrégé: Stroke
Pays: United States
ID NLM: 0235266

Informations de publication

Date de publication:
Jul 2024
Historique:
medline: 24 6 2024
pubmed: 24 6 2024
entrez: 24 6 2024
Statut: ppublish

Résumé

The decision to treat an incidental finding in an asymptomatic patient results from careful risk-benefit consideration and is often challenging. One of the main aspects is after how many years the group who underwent the intervention and faced the immediate treatment complications will gain a treatment benefit over the conservatively managed group, which maintains a lower but ongoing risk. We identify a common error in decision-making. We illustrate how a risk-based approach using the classical break-even point at the Kaplan-Meier curves can be misleading and advocate for using an outcome-based approach, counting the cumulative number of lost quality-adjusted life years instead. In clinical practice, we often add together the yearly risk of the natural course up to the time point where the number equals the risk of the intervention and assume that the patient will benefit from an intervention beyond this point in time. It corresponds to the crossing of the Kaplan-Meier curves. However, because treatment-related poor outcome occurs at the time of the intervention, while the poor outcome in the conservative group occurs over a given time period, the true benefit of retaining more quality-adjusted life years in the interventional group emerges at a much later time. To avoid overtreatment of patients with asymptomatic diseases, decision-making should be outcome-based with counting the cumulative loss of quality-adjusted life years, rather than risk-based, comparing the interventional risk with the ongoing yearly risk of the natural course.

Identifiants

pubmed: 38913793
doi: 10.1161/STROKEAHA.123.045106
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1951-1955

Auteurs

Andreas Raabe (A)

Department of Neurosurgery (A.R., D.B., J. Goldberg, I.Z.), Inselspital, Bern University Hospital, Switzerland.

Urs Fischer (U)

Department of Neurology, University Hospital Basel, University of Basel, Switzerland (U.F.).

Peter M Rothwell (PM)

Nuffield Department of Clinical Neurosciences (P.M.R.), University of Oxford, United Kingdom.

Ramon Luengo-Fernandez (R)

Health Economics Research Centre (R.L.-F.), University of Oxford, United Kingdom.

David Bervini (D)

Department of Neurosurgery (A.R., D.B., J. Goldberg, I.Z.), Inselspital, Bern University Hospital, Switzerland.

Johannes Goldberg (J)

Department of Neurosurgery (A.R., D.B., J. Goldberg, I.Z.), Inselspital, Bern University Hospital, Switzerland.

Sven Trelle (S)

Clinical Trials Unit, Department of Clinical Research, University of Bern, Switzerland (S.T.).

Jan Gralla (J)

Department of Diagnostic and Interventional Neuroradiology (J. Gralla), Inselspital, Bern University Hospital, Switzerland.

Jürgen Beck (J)

Department of Neurosurgery, Medical Center, University of Freiburg, Germany (J.B.).

Irena Zubak (I)

Department of Neurosurgery (A.R., D.B., J. Goldberg, I.Z.), Inselspital, Bern University Hospital, Switzerland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH